Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433417 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTLMNAMDM4MDM2 | |
| SCHEMBL29623844 | 0.73 | CYP2C19 (0.46) | SMN1; SMN2MAPTLMNAMDM4MDM2 | |
| SCHEMBL14917146 | 0.72 | TGM2 (0.41) | SMN1; SMN2MAPTLMNAALDH1A1CYP3A4 | |
| SCHEMBL433286 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL11664515 | 0.71 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTLMNAMDM4MDM2 | |
| SCHEMBL11672524 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTLMNAMDM4MDM2 | |
| SCHEMBL17845998 | 0.69 | CYP2C19 (0.42) | SMN1; SMN2LMNAALDH1A1CYP2C19 | |
| SCHEMBL434126 | 0.67 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21798477 | 0.66 | TDP1 (0.46) | SMN1; SMN2MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL732002 | 0.66 | ATM (0.50) | SMN1; SMN2MAPTLMNAALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | SMN1; SMN2 4213/4885MAPT 4395/4885LMNA 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.